Companies › Guangzhou Virotech Pharmaceutical
3 active drug programs in 58 registered trials: 42 Phase 2, 9 Phase 3, 7 Phase 1; Oncology, Other; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VRT106 Recombinant oncolytic virus M1 | – | Phase 2 | Diffuse Midline Glioma, H3 K27M-Mutant; HCC; Solid Tumor; Solid Tumors … | Sep 2027 |
| Rivoceranib Vascular endothelial growth factor receptor 2 inhibitor | KDR | Phase 2 | HCC; Hepatocellular Carcinoma; Advanced Breast Cancer; Acral Melanoma … | Dec 2028 |
| M1-c6v1 | – | Phase 1 | Solid Tumor | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04560127 | Rivoceranib | Phase 2 | Radioactive Iodine-refractory Differentiated Thyroid Cancer | Oncology | Dec 2025 |
| NCT06429696 | Rivoceranib | Phase 2 | Small Cell Lung Cancer Extensive Stage | Oncology | Apr 2026 |
| NCT06349317 | Rivoceranib | Phase 2 | Hepatocellular Carcinoma | Oncology | May 2026 |
| NCT05198609 | Rivoceranib | Phase 3 | Hepatocellular Carcinoma | Oncology | Jul 2026 |
| NCT05139095 | Rivoceranib | Phase 2 | Gestational Trophoblastic Neoplasia | Other | Dec 2026 |
| NCT05451290 | Rivoceranib | Phase 2 | Advanced Biliary Tract Carcinoma | Oncology | Dec 2026 |
| NCT04208347 | Rivoceranib | Phase 2 | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Oncology | Dec 2026 |
| NCT06576973 | Rivoceranib | Phase 2 | Esophageal Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT06454578 | Rivoceranib | Phase 2 | Carcinoma, Hepatocellular | Oncology | Dec 2026 |
| NCT04331093 | Rivoceranib | Phase 2 | Acral Melanoma | Oncology | Dec 2026 |
| NCT06749730 | Rivoceranib | Phase 2 | Unresectable Biliary Tract Carcinoma | Oncology | Dec 2026 |
| NCT06475209 | Rivoceranib | Phase 2 | SCLC | Oncology | Dec 2026 |
| NCT05062837 | Rivoceranib | Phase 2 | Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT06099821 | Rivoceranib | Phase 2 | Digestive System Cancers | Oncology | Dec 2026 |
| NCT06831175 | Rivoceranib | Phase 2 | Adrenal Cortical Carcinoma | Oncology | Dec 2026 |
| NCT05447702 | Rivoceranib | Phase 2 | Triple Negative Breast Cancer | Oncology | Dec 2026 |
| NCT06700421 | Rivoceranib | Phase 2 | Unresectable Locally Advanced Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06418594 | Rivoceranib | Phase 2 | HER2-negative Breast Cancer Brain Metastases | Oncology | Dec 2026 |
| NCT06447623 | Rivoceranib | Phase 3 | Advanced Breast Cancer | Oncology | Feb 2027 |
| NCT05789043 | Rivoceranib | Phase 3 | Acral Melanoma | Oncology | Feb 2027 |
| NCT06296563 | Rivoceranib | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Mar 2027 |
| NCT07479732 | Rivoceranib | Phase 1 | Osteosarcoma | Oncology | Mar 2027 |
| NCT06360042 | Rivoceranib | Phase 2 | Unresectable Hepatocellular Carcinoma | Oncology | Mar 2027 |
| NCT05699655 | Rivoceranib | Phase 2 | Immunotherapy Gastrict Cancer | Oncology | Apr 2027 |
| NCT06913777 | Rivoceranib | Phase 3 | Neoadjuvant Therapy | Other | Apr 2027 |
| NCT06792162 | Rivoceranib | Phase 2 | Gastric Cancer | Oncology | Apr 2027 |
| NCT07157969 | Rivoceranib | Phase 2 | HCC - Hepatocellular Carcinoma | Oncology | Jun 2027 |
| NCT07135544 | Rivoceranib | Phase 2 | Biliary Tract Cancer | Oncology | Jun 2027 |
| NCT05759572 | Rivoceranib | Phase 2 | Breast Cancer Metastatic | Oncology | Jul 2027 |
| NCT07105748 | Rivoceranib | Phase 2 | Mixed Hepatocellular-cholangiocarcinoma | Oncology | Aug 2027 |
| NCT06607770 | Rivoceranib | Phase 1 | Lung Cancer | Oncology | Aug 2027 |
| NCT04072042 | Rivoceranib | Phase 2 | Sarcoma | Oncology | Sep 2027 |
| NCT06368921 | VRT106 | Phase 1 | Solid Tumor | Oncology | Sep 2027 |
| NCT07289997 | Rivoceranib | Phase 2 | AFP Gastric or Gastroesophageal Junction Adenocarcinoma | Oncology | Sep 2027 |
| NCT05854849 | Rivoceranib | Phase 3 | Nasopharyngeal Carcinoma | Oncology | Dec 2027 |
| NCT06749691 | Rivoceranib | Phase 2 | Small Cell Lung Cancer Extensive Stage | Oncology | Dec 2027 |
| NCT06925243 | Rivoceranib | Phase 3 | Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]) | Oncology | Dec 2027 |
| NCT06693128 | Rivoceranib | Phase 2 | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Oncology | Dec 2027 |
| NCT07311408 | Rivoceranib | Phase 2 | Gastric Cancer (GC) | Oncology | Jan 2028 |
| NCT07353684 | Rivoceranib | Phase 2 | Adebrelimab | Oncology | Feb 2028 |
| NCT07687433 | Rivoceranib | Phase 2 | Rectal Cancer Patients | Oncology | May 2028 |
| NCT07589257 | VRT106 | Phase 2 | Diffuse Midline Glioma, H3 K27M-Mutant | Oncology | Jun 2028 |
| NCT06485466 | Rivoceranib | Phase 3 | Unresectable Hepatocellular Carcinoma | Oncology | Jun 2028 |
| NCT05069857 | Rivoceranib | Phase 2 | Oral Squamous Cell Carcinoma | Oncology | Jun 2028 |
| NCT06046742 | M1-c6v1 | Phase 1 | Solid Tumor | Oncology | Jun 2028 |
| NCT06826313 | VRT106 | Phase 1 | Solid Tumors | Oncology | Dec 2028 |
| NCT07569679 | Rivoceranib | Phase 2 | Biliary Tract Cancer | Oncology | Dec 2028 |
| NCT07589244 | VRT106 | Phase 2 | HCC | Oncology | Dec 2028 |
| NCT07093814 | VRT106 | Phase 1 | Glioblastoma | Oncology | Dec 2028 |
| NCT07589244 | Rivoceranib | Phase 2 | HCC | Oncology | Dec 2028 |
| NCT06181032 | Rivoceranib | Phase 1 | Biliary Tract Malignancies | Oncology | Feb 2029 |
| NCT06438627 | Rivoceranib | Phase 3 | Nasopharyngeal Carcinoma | Oncology | May 2029 |
| NCT07267806 | Rivoceranib | Phase 3 | Hepato Cellular Carcinoma (HCC) | Oncology | Oct 2029 |
| NCT07026149 | Rivoceranib | Phase 2 | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Oncology | May 2030 |
| NCT02485015 | Rivoceranib | Phase 2 | Stomach Neoplasms | Oncology | Jun 2030 |
| NCT02493582 | Rivoceranib | Phase 2 | Adenocarcinoma of Lung | Oncology | Jul 2030 |
| NCT04666090 | Rivoceranib | Phase 2 | Esophageal Squamous Cell Carcinoma | Oncology | Nov 2030 |
| NCT03982485 | Rivoceranib | Phase 2 | Breast Cancer | Oncology | Mar 2031 |
Hutchmed Exelixis Merck & Co. (MSD) Jiangsu HengRui Medicine Chia Tai Tianqing Pharmaceutical Group Takeda AO GENERIUM Chipscreen Biosciences Avalyn Pharma Mannkind
GrandPharma (China) Criterium Diakonos Oncology Vyriad HRYZ Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.